News By Tag
* Drug Discovery
* More Tags...
News By Location
tebu-bio launches SilenciX in the USA in partnership with SABiosciences
tebu-bio, in partnership with SABiosciences (Frederick, MD), is pleased to announce the launch of SilenciX cell lines in the USA
By: Sara Pierre, tebu-bio
The innovative technology is based on non-viral transfections of non-integrative vectors. The episomal vectors are maintained tethered to the host chromosomes, at a very low copy number per cell allowing long-term studies, consistent large cell supplies and high reproducibility in experiments, with no additional stress related to cell transfections.
Guaranty of target-specific knock-down at RNA level is at least 70%, cell lines produced so far mostly show over 85% silencing. Design of shRNAs is powered by the new DSIR algorithm for the prediction of RNAi efficacy and off-target blast screening.
Aurélie Serra (Product Manager - tebu-bio) adds " We are pleased that our partnership with SABiosciences will enable American scientists to have access to these reliable tools for target validation and drug discoveries in Life Sciences".
For further information about SilenciX from tebu-bio in Europe, please contact Aurélie Serra (aurelie.serra@
To find out more about SilenciX in the USA from SABiosciences, please contact Shankar Sellappan (SSellappan@
# # #
tebu-bio is an expert in the supply and distribution of Life Sciences research reagents in Europe, their own laboratories also provide R&D contract services. The tebu-bio.com catalogue (http://www.tebu-